Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Preferred Stock Liabilities (2022 - 2023)

Serina Therapeutics' Preferred Stock Liabilities history spans 1 years, with the latest figure at $36.4 million for Q4 2023.

  • For Q4 2023, Preferred Stock Liabilities changed N/A year-over-year to $36.4 million; the TTM value through Dec 2023 reached $36.4 million, changed N/A, while the annual FY2023 figure was $36.4 million, N/A changed from the prior year.
  • Preferred Stock Liabilities for Q4 2023 was $36.4 million at Serina Therapeutics.
  • Across five years, Preferred Stock Liabilities topped out at $36.4 million in Q4 2023 and bottomed at $36.4 million in Q4 2023.